Ann: Breakthrough Zantrene Heart Protection Discovery, page-68

Transcript (unedited):



[Music]
this is amazing discovery what we've
discovered is we've known for a long
time that the santorini is not damaging
to the heart
but we haven't known um if it would be
protective
to the heart what we've discovered is
that if you add pysantrine to other
drugs that damage the heart we can
protect them
that damage and this is
changes the whole dynamic of how you
might use xantrine instead of having to
replace the existing drugs which are
really well known they're known as
anthracyclines
you can actually add them keep the
anthracycline adding percentage to it
and protect the damage from the heart
this opens up
amazing opportunity
clinically commercially
and it also
the other amazing thing is in
combination between those two drugs you
get better treatment of the cancer so
the cancers are killed at much lower
concentrations of the drug
much more effectively and the
resistance to those drugs is not
perfect and so they don't overlap and
you end up with a result
where the patient's cancer is much
better treated they would be by the drug
alone
amazing discovery
really unexpected
[Music]
well interestingly pillar two was always
about breast cancer and we always had
shared that we were progressing our
credentials in breast cancer because of
our cardio toxic or less cardio toxic
properties
really this is an evolution but a
significant evolution because it means
that
it's beyond us being less cardiotoxic in
being cardio protective it means that
pillar two has genuine
significant clinician interest so if we
take it through the clinic successfully
clinicians can continue to prescribe
anthracyclines as they do but they can
use them with more confidence knowing
that
heart damage is greatly reduced we hope
and that would that would really create
a very significant outcome for what was
or what is pillar ii in breast cancer
well
two things
one that it means that they can actually
be treated
at the moment many cancer patients get
really sub-optimal treatment so the
oncologists are so scared
of the damage to the heart
that they won't treat the patient so
they'll give them lower doses or they'll
give them fewer doses and the cancer is
not treated fully
the other thing that allows this is it
takes away the major risk of getting a
or potentially takes away the major risk
that comes with this treatment and that
damage to the heart and that's
unpredictable
sometimes patients even given a low dose
of the drug
suffer long-term consequences and
the doctors don't know before they're
treated if that happens or not
[Music]
well it's of course significant because
if you think about anthracyclines as a
class
they're the most used cancer drug in the
world
had been for many years continue to be
and if you think about what we've
discovered and understood potentially in
every application of an
anthracycline you would equally apply
xantrine so that combination means that
potentially there are millions and
millions of potential treatment
opportunities so if you aggregate that
in value it's it's an enormous number um
you know so we and we'll do our work and
we'll figure that out in due course but
it's an enormous number so
commercially if you think about how you
might commercialize we can we can
sell zantran independently and it can be
used adjunctively with anthracyclines
potentially we could co-formulate and
have co-formulated products and
solutions that might be easier to use in
the clinic
we can license we can partner there's
enormous range of opportunities that
will be explored of course down the road
no it's um
it was always been known that it's been
safer drug but it's not been known how
or why
and
i had the hypothesis that maybe it
actually wasn't just a safer drug maybe
it was actually able to undo the damage
that these class drugs do
and
so we set off with an experiment and to
look at this and we discovered that
actually it's not only a safer drug it's
actually a protective drug and it
protects against the damage caused by
the anthracyclines
amazing outcome
couldn't ask for a better result
except maybe the discovery that
sanctuary targets fto
[Music]
well our ip position is in bolt embolden
because of course we can file ip against
its discovery
secondly we can formulate and with that
formulation we can develop additional ip
for that particular
use and application so it really does
broaden our pattern of state
traditionally our patents are being
established in a certain area in class
but this certainly broadens it
significantly so we're really blessed we
have a drug that's already in the clinic
has a lot of clinical history it's been
in 600
more than 1500 patients in more than 60
clinical trials we currently have the
drug
in the clinical trial right now running
in israel we're about to start a trial
here
here in australia so we have the ability
to really quickly translate this
discovery from the laboratory into the
clinic and actually make a difference to
patients and so we're intending to run
clinical trial
in 2022 so we have this ability to
really quickly move this forward this is
not a discovery that's maybe five years
away maybe 10 years away if everything
works out this is something that will
happen next year
and opens up a massive opportunity
for the company and for patients
and i think it's really exciting
exciting discovery
[Music]